Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Dec
09
Today In Oncology
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
Impact of Prevention and Screening on Mortality From Five Common Cancers
Cancer Risk Associated With Use of Disease-Modifying Antirheumatic Drugs
Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer
Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo